mini-hyperCVD

Phase 2Small molecule

UUniversity of Chicago

mini-hyperCVD is one of 51 small molecule programs targeting Chemotherapy. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ChemotherapyRecruiting

ChemotherapyPhase 2

Recruiting

Competition

Competitive Landscape

109 competitors in Chemotherapy

#DrugCompanyPhaseTrials

Taxol

Teva

Phase 3

20 2

Eloxatin

Teva

Phase 3

13 3

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

31 4

Cytosar

Teva

Phase 3

11 5

Avastin

Roche

Phase 3

11 6

Imfinzi

AstraZeneca

Phase 3

8 7

Camptosar

Pfizer

Phase 3

8 8

Vepesid

AAvyxa

Phase 3

22 9

Opdivo

Bristol-Myers Squibb

Phase 3

7 10

Gemzar

Johnson & Johnson

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2032

Phase 1/2Recruiting

Chemotherapy

NCT07294677

Clinical

Trials by Indication[1]

Chemotherapy1 trial

CApivasertib, Venetoclax And Low-intensity chemotheRapY for Adults With ALL/LBL

Recruiting·UUniversity of Chicago·Phase 1/2·NCT07294677·104 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for mini-hyperCVD. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — mini-hyperCVD compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for mini-hyperCVD. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Chicago company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: UUniversity of Chicago

mini-hyperCVD

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2032

Trials by Indication[1]

Chemotherapy1 trial

References

Drug Info

Quick Facts

Related News